Glioblastoma: Molecular pathways, stem cells and therapeutic targets

Cancers

Volumn 7, Issue 2, 2015, Pages 538-555

  Jhanwar Uniyal, Meena ^a   Labagnara, Michael ^a   Friedman, Marissa ^a   Kwasnicki, Amanda ^a   Murali, Raj ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Brain tumors; Cancer stem cells; GBM; MTOR; Therapies

Indexed keywords

CARMUSTINE; DENDRITIC CELL VACCINE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SITIMAGENE CERADENOVEC; TEMOZOLOMIDE;

CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER STEM CELL; CARCINOGENESIS; DRUG EFFICACY; GLIOBLASTOMA; HUMAN; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW;

EID: 84925844887     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers7020538     Document Type: Review

References (87)

1. Lawrence, Y.R.; Mishra, M.V.; Werner-Wasik, M.; Andrews, D.W.; Showalter, T.N.; Glass, J.; Shen, X.; Symon, Z.; Dicker, A.P. Improving prognosis of glioblastoma in the 21st century: Who has benefited most? Cancer 2012, 118, 4228–4234. [CrossRef] [PubMed]
2. Wen, P.Y.; Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359, 492–507.
3. Ostrom, Q.T.; Gittleman, H.; Liao, P.; Rouse, C.; Chen, Y.; Dowling, J.; Wolinsky, Y.; Kruchko, C.; Barnholtz-Sloan, J. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. NeuroOncology 2014, 16, 1–63.
4. Furnari, F.B.; Fenton, T.; Bachoo, R.M.; Mukasa, A.; Stommel, J.M.; Stegh, A.; Hahn, W.C.; Ligon, K.L.; Louis, D.N.; Brennan, C.; et al. Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev. 2007, 21, 2683–2710. [CrossRef] [PubMed]
5. Watanabe, K.; Tachibana, O.; Sata, K.; Yonekawa, Y.; Kleihues, P.; Ohgaki, H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996, 6, 217–223. [CrossRef] [PubMed]
6. Arjona, D.; Rey, J.A.; Taylor, S.M. Early genetic changes involved in low-grade astrocytic tumor development. Curr. Mol. Med. 2006, 6, 645–650. [CrossRef] [PubMed]
7. Parsons, D.W.; Jones, S.; Zhang, X.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I.M.; Gallia, G.L.;. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321, 1807–1812. [CrossRef] [PubMed]
8. Yan, H.; Parsons, D.W.; Jin, G.; McLendon, R.; Rasheed, B.A.; Yuan, W.S.; Kos, I.; Batinic-Haberle, I.; Jones, S.; Riggins, G.J.; et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360, 765–773. [CrossRef] [PubMed]
9. Ohgaki, H.; Kleihues, P. The definition of primary and secondary glioblastoma. Clin. Cancer Res. 2013, 19, 764–772. [CrossRef] [PubMed]
10. Nobusawa, S.; Lachuer, J.; Wierinckx, A.; Kim, Y.H.; Huang, J.; Legras, C.; Kleihues, P.; Ohgaki, H. Intratumoral patterns of genomic imbalance in glioblastomas. Brain Pathol. 2010, 20, 936–944. [PubMed]
11. Phillips, H.S.; Kharbanda, S.; Chen, R.; Forrest, W.F.; Soriano, R.H.; Wu, T.D.; Misra, A.; Nigro, J.M.; Colman, H.; Soroceanu, L.; Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9, 157–173. [CrossRef] [PubMed]
12. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455, 1061–1068.
13. Verhaak, R.G.; Hoadley, K.A.; Purdom, E.; Wang, V.; Qi, Y.; Wilkerson, M.D.; Miller, C.R.; Ding, L.; Golub, T.; Mesirov, J.P.; et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17, 98–110. [CrossRef] [PubMed]
14. Noushmehr, H.; Weisenberger, D.J.; Diefes, K.; Phillips, H.S.; Pujara, K.; Berman, B.P.; Pan, F.; Pelloski, C.E.; Sulman, E.P.; Bhat, K.P.; et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17, 510–522. [CrossRef] [PubMed]
15. Motomura, K.; Natsume, A.; Watanabe, R.; Ito, I.; Kato, Y.; Momota, H.; Nishikawa, R.; Mishima, K.; Nakasu, Y.; Abe, T. et al. Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas. Cancer Sci. 2021, 103, 1871–1879.
16. Louis, D.N.; Perry, A.; Burger, P.; Ellison, D.W.; Reifenberger, G.; von Deimling, A.; Aldape, K.; Brat, D.; Collins, V.P.; Eberhart, C. et al. International society of neuropathology-haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 2014, 24, 429–435. [CrossRef] [PubMed]
17. Zeppernick, F.; Ahmadi, R.; Campos, B.; Dictus, C.; Helmke, B.M.; Becker, N.; Lichter, P.; Unterberg, A.; Radlwimmer, B.; Herold-Mende, C.C. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res. 2008, 14, 123–129. [CrossRef] [PubMed]
18. Piccirillo, S.G.; Combi, R.; Cajola, L.; Patrizi, A.; Redaelli, S.; Bentivegna, A.; Baronchelli, S.; Maira, G.; Pollo, B.; Mangiola, A. et al. Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene 2009, 28, 1807–1811. [CrossRef] [PubMed]
19. Singh, S.K.; Hawkins, C.; Clarke, I.D.; Squire, J.A.; Bayani, J.; Hide, T.; Henkelman, R.M.; Cusimano, M.D.; Dirks, P.B. Identification of human brain tumour initiating cells. Nature 2004, 432, 396–401. [CrossRef] [PubMed]
20. Calabrese, C.; Poppleton, H.; Kocak, M.; Hogg, T.L.; Fuller, C.; Hamner, B.; Oh, E.Y.; Gaber, M.W.; Finklestein, D.; Allen, M. et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11, 69–82. [CrossRef] [PubMed]
21. Ding, B.-S.; James, D.; Iyer, R.; Falciatori, I.; Hambardzumyan, D.; Wang, S.; Butler, J.M.; Rabbany, S.Y.; Hormigo, A. Prominin 1/CD133 endothelium sustains growth of proneural glioma. PLOS ONE 2013. [CrossRef]
22. Wang, J.; Sakariassen, P.ß.; Tsinkalovsky, O.; Immervoll, H.; Bøe, S.O.; Svendsen, A.; Prestegarden, L.; Røsland, G.; Thorsen, F.; Stuhr, L. et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int. J. Cancer 2008, 122, 761–768.
23. Kelly, J.; Stechishin, O.; Chojnacki, A.; Lun, X.; Sun, B.; Senger, D. L.; Forsyth, P.; Auer, R.N.; Dunn, J.F.; Cairncross, J.G. et al. Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens. Stem Cells 2009, 27, 1722–1733. [CrossRef] [PubMed]
24. Prestegarden, L.; Svendsen, A.; Wang, J.; Sleire, L.; Skaftnesmo, K.O.; Bjerkvig, R.; Yan, T.; Askland, L.; Persson, A.; Sakariassen, P.O. et al. Glioma cell populations grouped by different cell type markers drive brain tumor growth. Cancer Res. 2010, 70, 4274–4279.
25. Zhao, W. Comparison of L1 Expression and secretion in glioblastoma and neuroblastoma cells. Oncol. Lett. 2012, 4, 812–816. [PubMed]
26. Brescia, P.; Richichi, C.; Pelicci, G. Current strategies for identification of glioma stem cells: Adequate or unsatisfactory? J. Oncol. 2012. [CrossRef]
27. Pietras, A.; Katz, A.; Wee, B.; Halliday, J.J.; Pitter, K.L.; Werbeck, J.L.; Amankulor, N.M.; Huse, J.T.; Holland, E.C. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell 2014, 14, 357–369. [CrossRef] [PubMed]
28. Dahlrot, R.H.; Hermansen, S.K.; Hansen, S.; Kristensen, B.W. What is the clinical value of cancer stem cell markers in gliomas? Int. J. Clin. Exp. Pathol. 2013, 6, 334–348. [PubMed]
29. Jacinto, E.; Hall, M.N. Tor signalling in bugs, brain and brawn. Nat. Rev. Mol. Cell Biol. 2003, 4, 117–126. [CrossRef] [PubMed]
30. Jhanwar-Uniyal, M.; Albert, L.; McKenna, E.; Karsy, M.; Rajdev, P.; Braun, A.; Murali, R. Deciphering the signaling pathways of cancer stem cells of glioblastoma multiforme: Role of Akt/mTOR and MAPK pathways. Adv. Enzym. Regul. 2011, 51, 164–170. [CrossRef]
31. Jhanwar-Uniyal Jeevan, D.; Neil, J.; Shannon, C.; Albert, L.; Murali, R. Deconstructing mTOR complexes in regulation of Glioblastoma Multiforme and its stem cells. Adv. Biol. Regul. 2013, 53, 202–210. [CrossRef] [PubMed]
32. Castilho, R.M.; Squarize, C.H.; Chodosh, L.A.; Williams, B.O.; Gutkind, J.S. mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell 2009, 5, 279–289.
33. Demidenko, Z.N.; Shtutman, M.; Blagosklonny, M.V. Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. Cell Cycle 2009, 8, 1896–1900. [CrossRef] [PubMed]
34. Korotchkina, L.G.; Leontieva, O.V.; Bukreeva, E.I.; Demidenko, Z. N.; Gudkov, A.V.; Blagosklonny, M.V. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging 2010, 2, 344–352. [PubMed]
35. Matsumoto, K.; Arao, T.; Tanaka, K.; Kaneda, H.; Kudo, K.; Fujita, Y.; Tamura, D.; Aomatsu, K.; Tamura, T.; Yamada, Y. et al. mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res. 2009, 69, 7160–7164. [CrossRef] [PubMed]
36. You, H.; Ding, W.; Rountree, C.B. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 2010, 51, 1635–1644. [CrossRef] [PubMed]
37. Platet, N.; Liu, S.Y.; Atifi, M.E.; Oliver, L.; Vallette, F.M.; Berger, F.; Wion, D. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett. 2007, 258, 286–290. [CrossRef] [PubMed]
38. McCord, A.M.; Jamal, M.; Shankavaram, U.T.; Lang, F.F.; Camphausen, K.; Tofilon, P.J. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol. Cancer Res. 2009, 7, 489–497. [CrossRef] [PubMed]
39. Persano, L.; Rampazzo, E.; Basso, G.; Viola, G. Glioblastoma cancer stem cells: Role of the microenvironment. Biochem. Pharmacol. 2013, 85, 612–622. [CrossRef] [PubMed]
40. Hudson, C.C.; Liu, M.; Chiang, G.G.; Otterness, D.M.; Loomis, D.C.; Kaper, F.; Giaccia, A.J.; Abraham, R.T. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 2002, 22, 7004–7014. [CrossRef] [PubMed]
41. Soeda, A.; Park, M.; Lee, D.; Mintz, A.; Ndroutsellis-Theotokis, A.; McKay, R.D.; Engh, J.; Iwama, T.; Kunisada, T.; Kassam, A.B. et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009, 28, 3949–3959.
42. Friedman, M.D.; Jeevan, D.; Tobias, M.; Murali, R.; Jhanwar-Uniyal, M. Targeting cancer stem cells of glioblastoma multiforme using mtor inhibitors and differentiating agent all-trans retinoic acid. Oncol. Rep. 2013, 30, 1645–1650. [PubMed]
43. Sato, A.; Sunayama, J.; Matsuda, K.; Seino, S.; Suzuki, K.; Watanabe, E.; Tachibana, K.; Tomiyama, A.; Kayama, T.; Kitanaka, C. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis. Stem Cells 2011, 29, 1942–1951. [CrossRef] [PubMed]
44. Shimizu, T.; Tolcher, A.W.; Papadopoulos, K.P.; Beeram, M.; Rasco, D.W.; Smith, L.S.; Gunn, S.; Smetzer, L.; Mays, T.A.; Kaiser, B. et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin. Cancer Res. 2012, 18, 2316–2325. [CrossRef] [PubMed]
45. Galanis, E.; Buckner, J.C.; Maurer, M.J.; Kreisberg, J.I.; Ballman, K.; Boni, J.; Peralba, J.M.; Jenkins, R.B.; Dakhil, S.R.; Morton, R.F. et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study. J. Clin. Oncol. 2005, 23, 5294–5304. [CrossRef] [PubMed]
46. Piccirillo, S.G.; Reynolds, B.A.; Zanetti, N.; Lamorte, G.; Binda, E.; Broggi, G.; Brem, H.; Olivi, A.; DiMeco, F.; Vescovi, A.L. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006, 444, 761–765.
47. Anido, J.; Sáez-Borderías, A.; Gonzàlez-Juncà, A.; Rodon, L.; Folch, G.; Carmona, M.A.; Prieto-Sanchez, R.M.; Barba, I.; Martinez-Saez, E.; Prudkin, L. et al. TGF-receptor inhibitors target the cd44(high)/id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 2010, 18, 655–668. [CrossRef] [PubMed]
48. Peñuelas, S.; Anido, J.; Prieto-Sánchez, R.M.; Folch, G.; Barba, I.; Cuartas, I.; Garcia-Dorado, D.; Poca, M.A.; Sahuquillo, J.; Baselga, J. et al. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 2009, 15, 315–327.
49. Seoane, J.; Le, H.V.; Shen, L.; Anderson, S.A.; Massague, J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 2004, 117, 211–223. [CrossRef] [PubMed]
50. Park, E.; Kim, G.; Jung, J.; Wang, K.; Lee, S.; Jeon, S.S.; Lee, Z.W.; Kim, S.I.; Kim, S.; Oh, Y.T. et al. Differential expression of MicroRNAs in patients with glioblastoma after concomitant chemoradiotherapy. OMICS 2013, 17, 259–268. [CrossRef] [PubMed]
51. Huse, J.; Holland, E. Targeting brain cancer: Advances in the molecular pathology of malignant glioma and medulloblastoma. Nat. Rev. Cancer 2010, 10, 319–331. [CrossRef] [PubMed]
52. Guo, P.; Nie, Q.; Lan, J.; Ge, J.; Qiu, Y.; Mao, Q. C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells. Biochem. Biophys. Res. Commun. 2013, 441, 186–190. [CrossRef] [PubMed]
53. Costa, P.M.; Cardoso, A.L.; Nóbrega, C.; Pereira de Almeida, L.F.; Bruce, J.N.; Canoll, P.; Pedroso de Lima, M.C. MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma. Hum. Mol. Genet. 2013, 22, 904–918.
54. Costa, P.M.; Cardoso, A.L.; Pereira de Almeida, L.F.; Bruce, J.N.; Canoll, P.; Pedroso de Lima, M.C. PDGF-B-mediated downregulation of miR-21: New insights into PDGF signaling in glioblastoma. Hum. Mol. Genet. 2013, 21, 5118–5130. [CrossRef]
55. Zhou, X.; Ren, Y.; Moore, L.; Mei, M.; You, Y.; Xu, P.; Wang, B.; Wang, G.; Jia, Z.; Pu, P. et al. Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab. Investig. 2010, 90, 144–155.
56. Yin, D.; Ogawa, S.; Kawamata, N. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene 2013, 32, 1155–1163. [CrossRef] [PubMed]
57. Ma, X.; Yoshimoto, K.; Guan, Y.; Hata, N.; Mizoguchi, M.; Sagata, N.; Murata, H.; Kuga, D.; Amano, T.; Nakamizo, A. et al. Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma. NeuroOncology 2012, 14, 1153–1162.
58. Aldaz, B.; Sagardoy, A.; Nogueira, L.; Guruceaga, E.; Grande, L.; Huse, J.T.; Aznar, M.A.; Díez-Valle, R.; Tejada-Solis, S.; Alonso, M.M. et al. Involvement of miRNAs in the differentiation of human glioblastoma multiforme stem-like cells. PLOS ONE 2013. [CrossRef]
59. Bier, A.; Giladi, N.; Kronfeld, N. MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget 2013, 4, 665–676. [PubMed]
60. Zhao, S.; Deng, Y.; Liu, Y.; Chen, X.; Yang, G.; Mu, Y.; Zhang, D.; Kang, J.; Wu, Z. MicroRNA-153 is tumor suppressive in glioblastoma stem cells. Mol. Biol. Rep. 2013, 40, 2789–2798. [CrossRef] [PubMed]
61. Alrfaei, B.M.; Vemuganti, R.; Kuo, J.S. microRNA-100 targets SMRT/NCOR2, reduces proliferation, and improves survival in glioblastoma animal models. PLOS ONE 2013. [CrossRef]
62. Asuthkar, S.; Velpula, K.K.; Chetty, C.; Gorantla, B.; Rao, J.S. Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity. Oncotarget 2012, 3, 1439–1454. [PubMed]
63. Gabriely, G.; Wurdinger, T.; Kesari, S.; Esau, C.C.; Burchard, J.; Linsley, P.S.; Krichevsky, A.M. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol. Cell. Biol. 2008, 28, 5369–5380. [CrossRef] [PubMed]
64. Chen, L.; Zhang, K.; Shi, Z.; Shi, Z.; Zhang, A.; Jia, Z.; Wang, G.; Pu, P.; Kang, C.; Han, L. A lentivirus-mediated miR-23b sponge diminishes the malignant phenotype of glioma cells in vitro and in vivo. Oncol. Rep. 2014, 31, 1573–1580. [PubMed]
65. Liu, Y.; Yan, W.; Zhang, W.; Chen, L.; You, G.; Bao, Z.; Wang, Y.; Wang, H.; Kang, C.; Jiang, T. MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1. Oncol. Rep. 2012, 28, 1013–1021. [PubMed]
66. Guessous, F.; Alvarado-Velez, M.; Marcinkiewicz, L.; Zhang, Y.; Kim, J.; Heister, S.; Kefas, B.; Godlewski, J.; Schiff, D.; Purow, B. et al. Oncogenic effects of miR-10b in glioblastoma stem cells. J. Neurooncol. 2013, 112, 153–163. [CrossRef] [PubMed]
67. Wong, S.T.; Zhang, X.Q.; Zhuang, J.T.; Chan, H.L.; Li, C.H.; Leung, G.K. MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells. Anticancer Res. 2012, 32, 2835–2841. [PubMed]
68. Ujifuku, K.; Mitsutake, N.; Takakura, S.; Matsuse, M.; Saenko, V.; Suzuki, K.; Hayashi, K.; Matsuo, T.; Kamada, K.; Nagata, I. et al. miR-195, miR-455-3p and miR-10a(*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett. 2012, 296, 241–248. [CrossRef]
69. Guo, P.; Lan, J.; Ge, J.; Nie, Q.; Guo, L.; Qiu, Y.; Mao, Q. MiR-26a enhances the radiosensitivity of glioblastoma multiforme cells through targeting of ataxia-telangiectasia mutated. Exp. Cell Res. 2014, 320, 200–208. [CrossRef] [PubMed]
70. Wang, Q.; Li, P.; Li, A.; Jiang, W.; Wang, H.; Wang, J.; Xie, K. Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J. Exp. Clin. Cancer Res. 2012.
71. Kwiatkowska, A.; Nandhu, M.; Behera, P.; Chiocca, E.A.; Viapiano, M.S. Strategies in gene therapy for Glioblastoma. Cancers 2013, 5, 1271–1305. [CrossRef] [PubMed]
72. Westphal, M.; Hilt, D.C.; Bortey, E. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. NeuroOncology 2003, 5, 79–88.
73. Westphal, M.; Yia-Herttuala, S.; Martin, J. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): A randomized, open-label, phase 3 trial. Lancet Oncol. 2013, 14, 823–833.
74. Moolten, F.L. Drug sensitivity (“suicide”) genes for selective cancer chemotherapy. Cancer Gene Ther. 1994, 1, 279–287. [PubMed]
75. Bi, W.L.; Parysek, L.M. Warnick, R.; Stambrook, P.J. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum. Gene Ther. 1993, 4, 725–731.
76. Asklund, T.; Appelskog, I.B.; Ammerpohl, O. Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene. Exp. Cell Res. 2003, 284, 185–195. [CrossRef] [PubMed]
77. Soudais, C.; Laplace-Builhe, C.; Kissa, K. Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo. FASEB J. 2001, 15, 2283–2285.
78. Thomas, C.E.; Edwards, P.; Wickham, T.J. Adenovirus binding to the coxsackievirus and adenovirus receptor or integrins is not required to elicit brain inflammation but is necessary to transduce specific neural cell types. J. Virol. 2002, 76, 3452–3460. [CrossRef] [PubMed]
79. Galluzzi, L.; Senovilla, L.; Vacchelli, E.; Eggermont, A.; Fridman, W.H.; Galon, J.; Sautes-Fridman, C.; Tartour, E.; Zitvogel, L.; Kroemer, G. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012, 1, 1111–1134. [CrossRef] [PubMed]
80. Aranda, F.; Vacchelli, E.; Eggermont, A.; Galon, J.; Sautes-Fridman, C.; Tartour, E.; Zitvogel, L.; Kroemer, G.; Galluzzi, L. Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology 2013. [CrossRef] [PubMed]
81. Chang, C.N.; Huang, Y.C.; Yang, D.M.; Kikuta, K.; Wei, K.J.; Kubota, T.; Yang, W.K. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J. Clin. Neurosci. 2011, 18, 1048–1054. [CrossRef] [PubMed]
82. Ardon, H.; van Gool, S.W.; Verschuere, T.; Maes, W.; Fieuws, S.; Sciot, R.; Wilms, G.; Demaerel, P.; Goffin, J.; Van Calenbergh, F. et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: Results of the HGG-2006 phase I/II trial. Cancer Immunol. Immunother. 2012, 61, 2033–2044.
83. Vleeschouwer, D.E.; Fieuws, S.; Rutkowski, S.; van Calenbergh, F.; van Loon, J.; Goffin, J.; Sciot, R.; Wilms, G.; Demaerel, P.; Warmuth-Metz, M. et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin. Cancer Res. 2008, 14, 3098–3104. [CrossRef] [PubMed]
84. Prins, R.; Soto, H.; Konkankit, V.; Odesa, S.K.; Eskin, A.; Yong, W.H.; Nelson, S.F.; Liau, L.M. Gene expression profile correlates with T cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin. Cancer Res. 2012, 17, 1603–1615.
85. Fong, B.; Jin, R.; Wang, X.; Safaee, M.; Lisiero, D.N.; Yang, I.; Li, G.; Liau, L.M.; Prins, R.M. Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLOS ONE 2012. [CrossRef]
86. Choi, B.; Archer, G.; Mitchell, D.; Heimberger, A.B.; McLendon, R.E.; Bigner, D.D.; Sampson, J.H. EGFRvIII-Targeted Vaccination Therapy of Malignant Glioma. Brain Pathol. 2009, 19, 713–723. [CrossRef] [PubMed]
87. Sampson, J.; Archer, G.; Mitchell, D.; Heimberger, A.B.; Herndon, J.E.; Lally-Goss, D.; Gehee-Norman, S.; Paolino, A.; Reardon, D.A.; Friedman, A.H. et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol. Cancer Ther. 2009, 8, 2773–2779. [CrossRef] [PubMed]